A Phase I Open-label Study for Subjects With Advanced Malignancies

Summary

This is a first-in-human (FIH) Phase 1 dose escalation study to evaluate the safety, tolerability, PK, PD, and preliminary activity of PT01 administered IV in subjects with advanced malignancies.'

Timeline

Start

2021-04-21

Primary completion

2022-12-01

Completion

2022-12-01

Drugs

Indications